THE Pharmaceutical Society of Australia (PSA) continues to lead on the quality use of medicines as part of a new consortium led by Palliative Care Australia (PCA).
The Quality Use of Community Palliative Care Medicines Project is set to deliver targeted education to prescribers, pharmacists and aged care nurses on critical palliative care medicines.
Supported by the Australian Government's Quality Use of Diagnostics, Therapeutics and Pathology Program, the consortium combines the expertise of Palliative Care Australia, PSA, Metro South Hospital and Health Service, and Ageing Australia to improve medicine safety and the safer use of the first nationally agreed National Core Community Palliative Care Medicines List.
PSA National President Assoc Prof Fei Sim said the project ensures that pharmacists are equipped to support and meet the complex needs of palliative care patients.
"Our role in supporting appropriate and safe use of medicines is even more important for palliative patients, where timely access to core medicines, particularly those that provide urgent symptom relief, can significantly impact patient comfort and quality of life.
"With 90 percent of Australians wanting to be cared for at home, this project will further develop important education and resources for pharmacists supporting palliative patients and carers with the medicines they need to manage pain and symptoms," Assoc Prof Sim concluded.
Camilla Rowland, CEO of PCA, highlighted the importance of education on critical palliative care medicines, noting that timely access to these medicines is essential to reduce suffering, avoid unnecessary hospital transfers, and respect the wishes of those who would prefer to die at home or in a community setting. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 09 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 May 25
